Chinese Pharma Industry News

12 February 1996

After four consecutive years of rapid growth averaging 23% a year, in 1994 China's pharmaceutical industry expanded by a further 13%, say local reports. State-owned enterprises contributed a great deal to this growth; they account for about 22% of the industry nationwide, and produced 65% of the sector's total output in 1994. Their sales and gross profits accounted for 81% and 91.3% of the national total.

Of the state-owned drug enterprises, the NorthEast China Pharmaceutical group Co, North China Pharmaceutical Group, harbin Pharmaceutical Factory and six others were among China's top 500 industrial enterprises in 1994, the sources note.

Moves To Ban Fake Drugs meantime, China's State Pharmaceutical Administration says over 80,000 cases of production and sales of substandard or fake medicines have been uncovered in the country since 1985. State Councillor Geng Peiyung has asked the SPA to begin a nationwide inspection early this year of all organizations producing and marketing medicines (Marketletter february 5).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight